[go: up one dir, main page]

NO20084747L - Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser - Google Patents

Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser

Info

Publication number
NO20084747L
NO20084747L NO20084747A NO20084747A NO20084747L NO 20084747 L NO20084747 L NO 20084747L NO 20084747 A NO20084747 A NO 20084747A NO 20084747 A NO20084747 A NO 20084747A NO 20084747 L NO20084747 L NO 20084747L
Authority
NO
Norway
Prior art keywords
inhibitors
useful
tetrahydropteridines
protein kinases
compounds
Prior art date
Application number
NO20084747A
Other languages
English (en)
Inventor
David Kay
Jean-Damien Charrier
Ronald Knegtel
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20084747L publication Critical patent/NO20084747L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser anvendelige som inhibitorer av protein kinase. Oppfinnelsen tilveiebringer også farmasøytisk akseptable sammensetninger som innbefatter nevnte forbindelser og fremgangsmåter for anvendelse av sammensetningene ved behandling av forskjellige sykdommer, tilstander eller forstyrrelser. Oppfinnelsen tilveiebringer også fremgangsmåter for fremstilling av forbindelsene ifølge oppfinnelsen.
NO20084747A 2006-04-12 2008-11-10 Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser NO20084747L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79132706P 2006-04-12 2006-04-12
US83872006P 2006-08-18 2006-08-18
PCT/US2007/009006 WO2007120752A2 (en) 2006-04-12 2007-04-12 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders

Publications (1)

Publication Number Publication Date
NO20084747L true NO20084747L (no) 2008-11-25

Family

ID=38544378

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084747A NO20084747L (no) 2006-04-12 2008-11-10 Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser

Country Status (16)

Country Link
US (3) US7763629B2 (no)
EP (1) EP2010542B1 (no)
JP (1) JP5313875B2 (no)
KR (1) KR101432316B1 (no)
AR (1) AR060432A1 (no)
AT (1) ATE542823T1 (no)
AU (1) AU2007238690B2 (no)
CA (1) CA2649324A1 (no)
ES (1) ES2381212T3 (no)
IL (1) IL194699A (no)
MX (1) MX2008013110A (no)
NO (1) NO20084747L (no)
NZ (1) NZ571969A (no)
RU (1) RU2441006C2 (no)
TW (1) TW200808805A (no)
WO (1) WO2007120752A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008287339A1 (en) * 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases
KR20100095020A (ko) 2007-12-19 2010-08-27 암젠 인크 세포 주기 억제제로서의 융합된 피리딘, 피리미딘 및 트리아진 화합물
AU2009233951B2 (en) 2008-04-07 2014-02-27 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2318412B1 (en) * 2008-06-23 2013-08-14 Vertex Pharmceuticals Incorporated Protein kinase inhibitors
NZ601453A (en) * 2008-06-23 2014-05-30 Vertex Pharma Protein kinase inhibitors
EP2480553A2 (en) * 2009-09-25 2012-08-01 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
ES2567280T3 (es) 2009-09-25 2016-04-21 Vertex Pharmaceuticals Incorporated Métodos para preparar derivados de pirimidina útiles como inhibidores de proteína quinasa
EP2516441B1 (en) 2009-12-23 2015-01-21 Elan Pharmaceuticals Inc. Pteridinones as inhibitors of polo-like kinase
JP5850321B2 (ja) * 2010-02-10 2016-02-03 公立大学法人横浜市立大学 神経選択的転写抑制因子ＮＲＳＦに特異的に結合するｍＳｉｎ３Ｂに結合する化合物の利用
CA2803446C (en) 2010-07-02 2019-06-04 University Health Network Use of plk4 antagonists for treating pten mutant diseases
AU2011311960A1 (en) 2010-10-08 2014-04-10 Elan Pharmaceuticals, Inc. Inhibitors of polo-like kinase
TW201307347A (zh) 2010-11-01 2013-02-16 Arqule Inc 經取代苯並－咪唑並－吡啶並－二氮呯化合物
MY161199A (en) 2011-03-23 2017-04-14 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
MD4300C1 (ro) * 2012-12-28 2015-03-31 Государственный Университет Молд0 Inhibitor al proliferării celulelor HepG2 în cancerul hepatic în bază de cloro-[2-fenil(piridin-2-il)metanon-4-(3-metoxifenil)tiosemicarbazono]nichel
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
SMT202300480T1 (it) 2016-03-28 2024-01-10 Incyte Corp Composti di pirrolotriazina come inibitori di tam
TWI821200B (zh) 2017-09-27 2023-11-11 美商英塞特公司 Tam抑制劑之鹽
PT3813800T (pt) 2018-06-29 2025-06-06 Incyte Corp Formulações de um inibidor de axl/mer
CN109734809A (zh) * 2019-02-27 2019-05-10 南方科技大学 治疗性的人Plk1蛋白单克隆抗体及其制备方法
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
US11912710B2 (en) * 2021-08-10 2024-02-27 Uppthera, Inc. Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2001019825A1 (en) * 1999-09-15 2001-03-22 Warner-Lambert Company Pteridinones as kinase inhibitors
WO2002076985A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
RU2351586C2 (ru) * 2002-10-03 2009-04-10 Таргеджен, Инк. Васкулостатические агенты и способы их применения
KR20120032574A (ko) * 2002-10-03 2012-04-05 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
MXPA05013478A (es) 2003-06-10 2006-03-09 Pfizer Combinaciones terapeuticas.
GB0315966D0 (en) * 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
GB0400700D0 (en) 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
GB0412874D0 (en) 2004-06-09 2004-07-14 Pfizer Ltd Novel pharmaceuticals
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
NZ571969A (en) 2011-10-28
US20120277425A1 (en) 2012-11-01
WO2007120752A3 (en) 2008-05-08
WO2007120752A2 (en) 2007-10-25
KR20080109919A (ko) 2008-12-17
AR060432A1 (es) 2008-06-18
RU2441006C2 (ru) 2012-01-27
US20110021519A1 (en) 2011-01-27
IL194699A0 (en) 2009-08-03
ES2381212T3 (es) 2012-05-24
AU2007238690B2 (en) 2013-05-02
US20090062292A1 (en) 2009-03-05
ATE542823T1 (de) 2012-02-15
KR101432316B1 (ko) 2014-08-29
CA2649324A1 (en) 2007-10-25
JP5313875B2 (ja) 2013-10-09
MX2008013110A (es) 2009-03-06
US8524902B2 (en) 2013-09-03
RU2008144584A (ru) 2010-05-20
US7763629B2 (en) 2010-07-27
TW200808805A (en) 2008-02-16
EP2010542A2 (en) 2009-01-07
AU2007238690A1 (en) 2007-10-25
EP2010542B1 (en) 2012-01-25
US8067417B2 (en) 2011-11-29
JP2009536155A (ja) 2009-10-08
IL194699A (en) 2014-07-31
HK1134486A1 (en) 2010-04-30

Similar Documents

Publication Publication Date Title
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
WO2008112651A3 (en) Aminopyrimidines useful as inhibitors of protein kinases
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
SG166828A1 (en) Aminopyrimidines useful as kinase inhibitors
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
MX2009011810A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
NO20084435L (no) C-MET proteinkinaseinhibitorer
MX2009012719A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
WO2007087283A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
WO2007139816A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
WO2007120760A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
NO20092130L (no) Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application